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Abstract: Host released alarmins and antimicrobial peptides (AMPs) are highly effective as 
antifungal agents and inducers. Whilst some are expressed constitutively at mucosal tissues, the 
primary site of many infections, others are elicited in response to pathogens. In the context of 
Candida albicans, the fungal factors inducing the release of these innate immune molecules are poorly 
defined. Herein, we identify candidalysin as a potent trigger of several key alarmins and AMPs 
known to possess potent anti-Candida functions. We also find extracellular ATP to be an important 
activator of candidalysin-induced epithelial signalling responses, namely epidermal growth factor 
receptor (EGFR) and MAPK signalling, which mediate downstream innate immunity during oral 
epithelial infection. The data provide novel mechanistic insight into the induction of multiple key 
alarmins and AMPs, important for antifungal defences against C. albicans. 
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1. Introduction 
Candida albicans is a highly prevalent fungal species found living harmoniously within the 
human body as part of a healthy microbiota [1]. However, under predisposing conditions, such as 
antibiotic treatment or host immunocompromise, C. albicans can infect mucosal tissues and 
potentially translocate across epithelial barriers to cause life-threatening systemic disease [2,3]. 
Suitably predisposing conditions may promote C. albicans hypha formation [4]; a dynamic, energy-
dependent process highly associated with pathogenicity and characterised by the secretion of the 
ECE1-encoded cytolytic peptide toxin, candidalysin [5–11]. Notably, candidalysin is secreted 
exclusively by pathogenic C. albicans hyphae and not commensal yeast, providing a unique 
mechanism for host cells to distinguish between potentially harmful and benign species, as well as 
initiate appropriate immune responses against this microbe. 
Oral epithelial cells respond directly to the presence of candidalysin by activating epidermal 
growth factor receptor (EGFR) [12], a key tyrosine kinase important in cell biology and infection [13]. 
Consequent MAPK signalling, via the AP-1 transcription factor c-Fos and MAPK phosphatase 
(MKP)-1 [14,15], as well as the release of inflammatory cytokines IL-1α, IL-1β, IL-36γ, IL-6, GM-CSF 
and G-CSF [12,14–20], follows EGFR activation. Candidalysin-induced IL-1α/β and IL-36γ signalling 
drives expansion of innate TCRαβ+ T-cells and consequent IL-17A expression, required for robust 
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antifungal immune responses at the oral mucosa [20,21]. A central theme of this immune response is 
neutrophil recruitment, which is mediated by candidalysin activity and is a key component for 
effective defences during oropharyngeal [5], systemic [22] and central nervous system (CNS) C. 
albicans infections [23]. Contrastingly, however, exacerbation of disease and immunopathology has 
also been observed as a consequence of neutrophil activity during vulvovaginal candidiasis [24,25], 
suggesting dysregulated immune control at this site. 
Though our understanding of the host immune response following C. albicans infections has 
greatly improved in recent years, details of initial activation events at the epithelial surface remain 
unclear. What is known, however, includes the immediate and early release of alarmins and 
antimicrobial peptides (AMPs) [26] in response to pathogenic C. albicans infection. Alarmins are a 
group of endogenous molecules secreted in response to cellular stresses that result from sterile 
inflammation or pathogen mediated injury. As such, alarmins provide warning signals that 
contribute to immune activation and tissue repair [27]. AMPs on the other hand, largely function to 
damage cell walls resulting in pathogen lysis, in addition to their immune-modulating abilities [28]. 
S100 proteins [29–31] and defensins [31–34] are highlighted as two main alarmin and AMP 
molecules induced by C. albicans, functioning to recruit neutrophils [29,30] and permeabilise fungal 
cell walls [35], respectively. However, information on the specific C. albicans factors that trigger the 
secretion of these molecules, or indeed other alarmins and AMPs, has largely remained elusive. 
Herein, we identify candidalysin as a potent stimulus of several key alarmins and AMPs including 
S100A8, human β-defensin (hBD)2, hBD3, the cathelicidin LL37, ATP and reactive oxygen and 
nitrogen species (ROS/RNS). Additionally, we highlight the importance of extracellular ATP in 
candidalysin-induced epithelial activation and immune signalling during C. albicans infection. 
2. Materials and Methods 
Cell culture: The human buccal epithelial squamous cell carcinoma cell line, TR146 [36], was 
obtained from the European Collection of Authenticated Cell Cultures (ECACC) and cultured in 
Dulbecco’s Modified Eagle’s Medium: Nutrient Mixture F12 (DMEM/F12, GIBCO, UK), 
supplemented with 10% foetal bovine serum and 1% penicillin–streptomycin. At 24 h prior to 
experimentation, the culture medium was replaced with serum-free medium and maintained until 
cells were harvested. 
C. albicans strains: BWP17+CIp30 [37] wild-type (WT), ece1Δ/Δ (ece1 null), ece1Δ/Δ+ECE1 and 
ece1Δ/Δ+ECE1Δ184-279 (see Supplementary Table or Reference [5] for full genotype information). C. 
albicans was cultured in YPD medium (1% yeast extract, 2% peptone, 2% dextrose in water) in a non-
airtight container, shaken at 200 rpm at 30 °C. Cultures were washed twice in PBS, prior to 
spectrophotometer analysis and diluted in appropriate culture media to the required concentration. 
A multiplicity of infection (MOI) of 5 was used for 2 h experiments and MOI 0.005 used with 24 h 
studies. 
Toxins: Candidalysin (SIIGIIMGILGNIPQVIQIIMSIVKAFKGNK) was synthesised by Peptide 
Protein Research Ltd (UK), solubilised in culture grade water and stored at 10 mg/mL at −20 °C. 
Nigericin was purchased from Sigma-Aldrich (Cat. No.: 481990-5), reconstituted in ethanol and 
stored at −20 °C. 
Inhibitors: Apyrase (#A6535 Sigma-Aldrich) was solubilised in ddH2O to a dilution of 1 mg/mL 
as recommended by the manufacturer, then used immediately or aliquoted and frozen for storage. 
Use of Apyrase within two weeks of reconstitution yielded optimum results. Tempol (Tocris #3082) 
was reconstituted in DMSO, aliquoted and frozen for storage (−20 °C) at 100 mg/mL or diluted into 
appropriate concentrations for immediate use. 
ELISA: Collected supernatants were centrifuged at 13000 rpm for 10 min prior to aliquoting and 
storage at −80 °C. ELISA kits were purchased from R&D Systems, (S100A8 Duoset kit, Oxfordshire, 
UK), Elabscience, (LL37, Oxfordshire, UK), LS Bio, (hBD3, Cambridge, UK) or Cusabio, (hBD1, 
Oxfordshire, UK) and performed according to the manufacturer’s instructions. hBD2 was detected in 
culture supernatants using the following reagents: goat anti-hBD2 primary antibody (#6500P161G 
Peprotech), recombinant hBD2 (#300-49, Peprotech), biotinylated goat anti-hBD2 (#500-P161GBt, 
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Peprotech), Streptavidin-HRP, substrate and stop solution (#DY999 R&D Systems). The following 
was conducted at room temperature with three PBS wash steps between each stage. Briefly, 
Maxisorp, Nunc 96-well plates were coated with 100 µL of primary antibody and incubated overnight 
at 4 °C. Wells were blocked with a 1% BSA solution at room temperature for 30 min, prior to addition 
of 100 µL samples/standards for 1.5 h. 100 µL of secondary antibody was then added at 0.1 µg/mL to 
wells for 60 min, followed by incubation with streptavidin-HRP (30 min), addition of substrate (5–20 
min) and stop solution (50 µL). Analysis was conducted at 450 nm within 30 min. 
ATP and ROS detection: Extracellular ATP was detected using an ATP Assay kit (#ab83355 
Abcam) according to the manufacturer’s instructions. Briefly, 50 µL standards and samples were 
added to a 96-well plate suitable for fluorescent analysis (black sides, clear bottom). A reaction 
mixture containing an ATP converter, probe, buffer and ‘developer mix’ was then added to all wells 
(50 µL) and incubated away from light at room temperature for 30 min. Analysis was conducted at 
535/587 nm within 2 h.  
Extracellular ROS/RNS was detected using the OxySelect In vitro ROS/RNS Assay Kit (#STA-
347, Cell Biolabs Inc) and performed as instructed by the manufacturer. Briefly, 50 µL of samples and 
standards were added in triplicate to a 96-well plate suitable for fluorescent analysis and incubated 
for 5 min. Addition of 50 µL Catalyst was then followed by a 100 µL Probe solution for 30 min. 
Fluorescence was analysed at 480 nm excitation / 530 emission. Data are expressed as the amount of 
relative fluorescent units (RFU) of dichlorodihydrofluorescin DiOxyQ (DCFH-DiOxyQ) or DCF 
probe detected. 
Western blotting: RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% 
Triton X-100, 1% sodium deoxycholate, 0.1% SDS) containing protease (Sigma-Aldrich) and 
phosphatase (Perbio Science) inhibitors was used to lyse cells following experimentation. Cell lysates 
were incubated in ice for 30 min after harvesting then centrifuged at 13,000 rpm at 4 °C for 10 min to 
remove debris before transfer to a new tube and storage at −80 °C. Protein concentration was 
determined using a BCA protein quantitation kit (Perbio Science) and 10 µg of total protein extract 
was separated on 12% acrylamide SDS-PAGE gels before transferring to nitrocellulose membranes 
(GE Healthcare). Membranes were incubated with primary (1:1000) and secondary (1:10000) 
antibodies before addition of immobilon chemiluminescent substrate (Millipore) and exposure to X-
ray film (Fiji film). Primary antibodies were all purchased Cell Signalling Technology: pEGFR Y1068 
(#3777S), c-Fos (#2250S), pMKP1 (#2857S) or Millipore: α-Actin (#MAB1501) 
MTT: MTT was purchased from Sigma-Aldrich (M5655) and prepared to 5 mg/mL in PBS and 
sterilised through a 0.2 µm filter. TR146 cells were seeded at a density of 2 × 105/mL in a flat-bottom 
96-well plate. The next day normal growth media was replaced with serum-free DMEM for 24 h. 
Serum-free DMEM alone or containing Apyrase or Triton X was added to wells in triplicate for 3 or 
25 h. This was followed by the addition of 20 µL MTT to all wells for 3 h at 37 °C. 150 µL of MTT 
solubilisation solution (50% dimethylformamide, 20 mM HCl, 0.2% glacial acetic acid and 10% SDS) 
diluted in deionised H2O) was then added to all wells and incubated overnight at 37 °C. Absorbance 
was measured at 620 nm wavelength. Values are calculated as a percentage of control (untreated 
wells). 
Cytokine quantification: A magnetic fluorokine performance MAP cytokine multiplex kit (Bio-
techne) was used alongside a Bioplex 200 machine to quantify levels of cytokine from culture 
supernatants. Antibody beads were purchased from Bio-techne and Bioplex manager 6.1 software 
was used to determine analyte concentrations. 
Statistics: One-way analysis of variance (ANOVA) was used alongside a Bonferroni post hoc test 
to correct for multiple comparisons. A p-value of less than 0.05 was considered significant and 
represented as *, while p< 0.01 = ** and p< 0.001 = ***. 
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3. Results 
3.1. Candidalysin Induces hBD2, hBD3 and LL37 Release During Oral C. Albicans Infection in Vitro 
A number of host-derived AMPs are induced during C. albicans mucosal infection. To investigate 
the role of candidalysin in AMP induction, we incubated TR146 oral epithelial cells with synthetic 
candidalysin or C. albicans fungal strains and analysed culture supernatants for hBD2, hBD3 and 
LL37. All three AMPs were significantly induced by candidalysin in a dose-dependent manner at 15 
min post-treatment and remained highly expressed for at least 6 h (Figure 1A–C). Moreover, 
candidalysin-deficient C. albicans strains (ece1Δ/Δ and ece1Δ/Δ+ECE1Δ184-279) were incapable of 
inducing hBD2 and hBD3 (Figure 1D,E (grey bars)) and significantly less inducive of LL37 as 
compared with wild-type (WT) C. albicans (Figure 1F (grey vs black bars)). The C. albicans ECE1 
recomplemented strain ece1Δ/Δ+ECE1, which produces candidalysin, was capable of near wild-type 
levels of AMP induction. Notably, hBD1 release was not triggered by candidalysin or C. albicans 
(Supplementary Figure 1A and B). 
 
Figure 1. Candidalysin induces secretion of antimicrobial peptides hBD2, hBD3 and LL37. All three 
molecules were secreted from oral epithelial cells 15 min post candidalysin treatment in a dose-
dependent manner (A–C). These proteins were also secreted following infection with candidalysin-
expressing C. albicans (D–F Black bars), but  deficiently secreted or not secreted at all in response C. 
albicans mutants lacking candidalysin (D–F grey bars). Infected cell supernatants were assayed at 24 
h post-infection (D–F) and are expressed as fold change relative to the vehicle control. Data are an 
average (A–E) or representative (F) of three biological experiments. Unmatched, one-way ANOVA 
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with Bonferroni multiple comparison’s test was used to assess statistical significance. Error bars 
represent SD, * p < 0.05, ** p < 0.01, *** p < 0.001. 
3.2. Candidalysin Promotes ATP, ROS/RNS and S100A8 Release  
We next assessed the role of candidalysin in inducing the epithelial alarmins ATP, ROS/RNS 
and S100A8. Given that ATP [38] and ROS [39] are produced by both Candida and epithelial cells, 
we used candidalysin alone as a stimulus to ensure the detection of host-produced alarmins only. 
Candidalysin induced the release of ATP (Figure 2A) and ROS/RNS (Figure 2B) in a dose-dependent 
manner, at 15 and 30 min post-treatment. No secretion of S100A8 was detected upon candidalysin 
treatment (Supplementary Figure 1C) but, interestingly, induction was observed following C. albicans 
infection (Figure 2C (black bars)), with candidalysin-deficient fungal mutants exhibiting diminished 
ability to trigger S100A8 release (Figure 2C (grey bars)). A modest and insignificant increase in 
HMGB1 induction was also observed upon candidalysin treatment at higher doses, but not following 
C. albicans infection (Supplementary Figure 1D and E). 
 
Figure 2. Candidalysin the induces release of ATP, ROS/RNS and S100A8 alarmins. ATP (A) and 
ROS/RNS (B) molecules are released from oral epithelial cells following treatment with 70 µM 
candidalysin. Initial elevated ATP levels are recovered at 2 h post-treatment, whereas increased 
ROS/RNS levels are maintained for 6 h. At 24 h post-infection, induction of S100A8 by candidalysin-
deficient strains is significantly suppressed (C (grey bars)) when compared to that of candidalysin-
expressing strains (C (black bars)). Data are an average of three biological experiments. Unmatched, 
one-way ANOVA with Bonferroni multiple comparison’s test was used to assess statistical 
significance. Error bars represent SD, * p < 0.05, ** p < 0.01, *** p < 0.001. 
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3.3. ATP Contributes to Epithelial Cell Activation and Signalling 
We previously reported the ability of candidalysin to induce EGFR activation and downstream 
MAPK signalling [12]. Given that both ATP [40] and ROS [41–43] are each capable of triggering EGFR 
activation, we investigated whether either of these molecules were involved in our model of 
candidalysin-induced EGFR activation. TR146 oral epithelial cells were incubated with the ATP 
hydrolysing enzyme, Apyrase, or ROS-scavenger, Tempol, prior to candidalysin treatment or C. 
albicans infection. Reduction in ATP levels via Apyrase treatment significantly suppressed epithelial 
responses to C. albicans, namely pEGFR, c-Fos, pMKP1 (Figure 3A) as well as IL-6 secretion (Figure 
3B), but not IL-1α, IL-1β, G-CSF or GM-CSF (Supplementary Figure 2A–D). Similarly, host responses 
to candidalysin were also significantly suppressed by Apyrase pre-treatment, which impaired 
pEGFR, c-Fos, pMKP1, IL-6, G-CSF and GM-CSF induction, though inhibition of G-CSF was not 
statistically significant (Figure 3C–F). However, no effect on candidalysin-induced hBD2, hBD3, LL37 
or IL-1α or IL-1β release was observed following Apyrase treatment (Supplementary Figure 2E–I). 
Notably, ROS inhibition via Tempol had no suppressive effect on C. albicans- or candidalysin-induced 
activation of pEGFR, c-Fos or pMKP1 (Supplementary Figure 3A,B). Given this, reduction in cytokine 
release was not assessed with Tempol. To ensure that Apyrase activity did not result in an overall 
loss of cellular fitness, we conducted a mitochondrial metabolic assessment (MTT assay) to determine 
TR146 cell viability following Apyrase treatment. Cell viability was not affected by Apyrase at 3 h or 
25 h post-treatment (Supplementary Figure 3C and D), confirming the importance of extracellular 
ATP in candidalysin-induced EGFR activation, MAPK signalling and consequent IL-6 induction. 
 
Figure 3. Reduction of available ATP suppresses candidalysin-triggered immune responses. Pre-
treatment of cells with the hydrolysing enzyme, Apyrase (10 µM), inhibited C. albicans- and 
candidalysin-induced pEGFR, c-Fos and pMKP1 (A and C), as well as IL-6 secretion (B and D). 
Candidalysin-induced G-CSF (E) and GM-CSF (F) were also suppressed following Apyrase pre-
treatment, though G-CSF inhibition was not statistically significant. Data are representative (A–C) or 
an average (D–F) of three biological experiments. Protein lysates and culture supernatants were 
harvested at 2 h and 24 h, respectively, post-stimulus. Unmatched, one-way ANOVA with Bonferroni 
multiple comparison’s test was used to assess statistical significance. Error bars represent SD, ** p < 
0.01, *** p < 0.001. 
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3.4. Candidalysin-Induced Responses are Specific and not a Consequence of General Pore Formation 
To determine the specificity of candidalysin-induced responses, we compared responses 
between candidalysin and nigericin, an unrelated pore-forming toxin from the bacterial species 
Streptomyces hygroscopicus. We found that nigericin was unable to induce ATP or ROS/RNS in oral 
epithelial cells (Figure 4A and B). While EGFR phosphorylation was induced, downstream MAPK 
components (c-Fos and MKP1) were not activated (Figure 4C). Thus, while nigericin forms pores and 
may activate EGFR, it does not induce a comparable biological response to that of candidalysin. The 
data suggest that ATP release (and subsequent downstream responses) is specific to candidalysin 
and not a consequence of general pore formation.  
 
Figure 4. Nigericin and candidalysin do not induce comparable effects. Pre-treatment of oral epithelial 
cells with nigericin at 20 µM or 10 µM does not induce ATP (A), ROS/RNS (B), c-Fos or pMKP1 (C); 
epidermal growth factor receptor (EGFR), however, is phosphorylated following nigericin treatment 
(C). Data are an average (A, B) or representative (C) of at least three biological experiments. Culture 
supernatants and protein lysates were harvested at 15 min and 2 h, respectively, post candidalysin 
stimulus. Unmatched, one-way ANOVA with Bonferroni multiple comparison’s test was used to 
assess statistical significance. Error bars represent SD, * p < 0.05. 
4. Discussion 
This study identifies candidalysin as a potent, hypha-specific inducer of alarmins and AMPs 
from human oral epithelial cells, and highlights the importance of ATP in initiating candidalysin-
induced signalling events required for downstream immune responses. 
A number of host protective AMPs and alarmins are induced in response to C. albicans infection 
within a variety of cell types, including human palate [33], vaginal [29] and oesophageal [32] 
epithelium, as well as human keratinocytes [44], blood-derived neutrophils [45] and the intestinal cell 
line Caco2 [34]. However, the identity of the specific fungal factors that trigger these alarmins and 
AMPs is largely unknown. C. albicans derived β-glucans [45] and phospholipomannan [44] have been 
reported as inducers of defensins in neutrophils and keratinocytes, respectively, but as components 
of the fungal cell wall, they are expressed by both C. albicans yeast and hyphae. Thus, whether they 
are associated with commensal homeostasis or pathogenic immunity is unclear, making it difficult to 
ascertain their importance during disease and subsequent host-immunity. Herein, we highlight 
candidalysin as the first hypha-specific C. albicans factor identified to trigger the release of multiple 
alarmins and AMPs in human oral epithelial cells. The data may be useful when considering novel 
anti-fungal strategies with specific regard to pathogenic C. albicans species. 
Upon C. albicans infection, the epithelial release of hBD2 and hBD3 are wholly attributed, and 
LL37 and S100A8 partially attributed, to candidalysin activity. Additionally, each molecule, except 
S100A8, is induced by candidalysin treatment alone. These observations in human oral epithelial cells 
align with previous studies highlighting the necessity for candidalysin in the induction of murine 
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BD3 and S100A gene transcripts during oropharyngeal [21] and vulvovaginal candidiasis [24]. 
Candidalysin independent mechanisms of S100A8 and LL37 release may also exist, as we find the 
absence of candidalysin does not completely abrogate induction of either protein during infection. 
Importantly, our findings also reveal an ability for candidalysin to induce epithelial-derived 
ATP and ROS/RNS alarmins. Contrastingly, the bacterial pore-forming toxin, nigericin, was unable 
to mimic this function, suggesting that release of alarmins is not a consequence of general pore 
formation at the epithelial membrane, but a specific and active response to candidalysin. We find 
initial elevated ATP levels return to normal within 2 h and may reflect the rapid hydrolysis of ATP 
to ADP/AMP in fuelling biological processes. Indeed, this short-lived elevation appears important in 
candidalysin-triggered responses, since reduced availability of ATP (via Apyrase) significantly 
inhibits EGFR activation, MAPK signalling (c-Fos, MKP1) and IL-6 release following infection or 
toxin treatment. In support of this, ATP-dependent transactivation of EGFR has been reported in 
airway epithelial cells, which is thought to occur via dual oxidase 1 (DUOX1) and disintegrin and 
metalloproteinase domain-containing protein (ADAM)-17 [40]. Given that activation of EGFR and 
downstream signalling are known to support protective anti-Candida immunity [5,12,24], the data 
may demonstrate a key role for ATP in triggering epithelial immune responses against C. albicans. 
The release of other known candidalysin-induced proteins, such as hBD2, hBD3, LL37, G-CSF, 
GM-CSF, IL-1α and IL-1β, do not appear to be affected by Apyrase during infection. Thus a 
combination of factors and underlying redundancy likely exist within the system, with events such 
as calcium influx, shown to have roles in ROS induction [46] and Candidalysin-induced immune 
responses [12], potentially playing a role. 
In addition to direct activation of epithelial cells, other anti-Candida functions of alarmins and 
AMPs are known to exist. These include recruitment of host protective neutrophils (S100 proteins 
[29,30] and defensins [31]), pathogen membrane permeabilisation (defensins [35] and LL37 [47]), 
attachment to cell wall proteins to inhibit host binding (LL37 [48]), as well as killing via induction of 
ionic destabilisation (histatins [49]) and generation of superoxides or hydrogen peroxide [50]. 
Together, these reports highlight the value of these molecules in anti-C. albicans immunity [31]. 
Herein, we identify a potent, C. albicans derived, hypha-specific inducer of alarmins and AMPs, 
and highlight ATP as an initiator of candidalysin-induced signalling events required for downstream 
protective immunity. The data allows for the first time, clear delineation of pathogen-specific 
responses in the context of alarmins and AMPs, providing new considerations to support anti-
Candida research and investigation. 
Supplementary Materials: The following are available online at www.mdpi.com, Figure S1: Candidalysin does 
not significantly stimulate hBD1, HMGB1 or S100A8 release. Figure S2: Cytokines and AMPs unaffected by 
Apyrase pre-treatment. Figure S3: ROS is not involved in candidalysin-induced cell signaling. Apyrase does not 
affect cell viability. , Table S1: Full genotypes of the C. albicans strains used. 
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